New Research Explores Wearable Technology Utilization in Clinical Trials and the Role of CROs
New Report Identifies Current and Future Wearable Technology Utilization and CRO Implications with 130 Clinical Outsourcing Decision Makers.
The data, representing input from small, mid-sized and large biopharmaceutical companies globally, indicate that biopharmaceutical companies are not yet fully educated on the rationale for and use of wearable technology in clinical trials, which presents an opportunity to those CROs investing time and resources in the capability.
“The findings are surprising. While many biopharma decision-makers are actively incorporating wearable technology into their clinical trials, a significant portion are not. Furthermore, many do not feel the need to do so. Our research uncovers key challenges limiting wearable technology use, and identifies opportunities for CROs to better serve the biopharmaceutical market,” said Jon Meyer, Life Science Strategy Group’s CRO Industry Practice Leader.
To learn more about LSSG’s new study revealing wearable technology trends and preparedness of leading CROs including Covance, ICON, inVentiv Health Clinical, INC Research, Parexel, PPD, PRA International and QuintilesIMS, please contact Life Science Strategy Group or click on the link below.
Wearable Technology Utilization in Clinical Trials and the Role of CROs
About Life Science Strategy Group, LLC
Life Science Strategy Group, LLC specializes in strategic consulting and market research engagements across a variety of therapeutic, technology and service industries including contract research services, pharmaceutical, biotechnology, medical devices, diagnostics and drug discovery.
Support InfoStride News' Credible Journalism: Only credible journalism can guarantee a fair, accountable and transparent society, including democracy and government. It involves a lot of efforts and money. We need your support. Click here to Donate